Digging deeper into the role of the T2DM and CRC core gene ENTPD3 in CRC anti-tumor immunity would be instrumental in optimizing the clinical values of ICIs in the era of immunotherapy, whether in terms of predictive biomarkers or improving immunotherapy efficiency. This evidence concerns the gene ENTPD3 and neoplasm.